Nexpring Health Invests in May Health to Advance Novel Fertility Solutions for Women with PCOS-Related Infertility
Nexpring Health, a globally recognized leader in assisted reproductive technology (ART) solutions, has announced a strategic investment in May Health, a medical device company pioneering innovative therapeutic approaches for women facing infertility related to polycystic ovary syndrome (PCOS). The investment, part of a €10 million ($11.7 million) funding round, was made alongside prominent investors including Sofinnova Partners, Trill Impact, and Bpifrance. This partnership highlights Nexpring Health’s ongoing commitment to supporting transformative solutions that go beyond traditional laboratory-based products, offering meaningful innovations to patients and fertility care professionals alike.
PCOS is the most common endocrine disorder among women of reproductive age and is recognized as one of the leading causes of female infertility. Globally, PCOS affects approximately 10–13% of women, presenting significant challenges for those trying to conceive. The condition often leads to irregular ovulation or, in some cases, the complete absence of ovulation, making conception a complex and difficult journey for many women. For decades, treatment options for PCOS-related infertility have been limited to first-line medications, lifestyle interventions, or assisted reproductive technologies, each with varying degrees of success. Despite these available options, many women still experience unmet needs, often due to non-responsiveness to medication, contraindications, or personal preferences that prevent them from pursuing conventional therapies.
Recognizing this critical gap in fertility care, May Health developed the Anavi™ System, a novel in-office therapeutic intervention designed to restore ovulation in women with PCOS-related infertility. The Anavi System represents a unique approach to addressing an unmet need in reproductive medicine. Unlike traditional treatments that may require extended medication regimens or complex assisted reproductive procedures, the Anavi System offers an in-office solution that can be administered safely and effectively, providing hope for women who have struggled to conceive through conventional methods. The system received CE marking under the EU MDR Regulation in October 2025, marking a significant milestone in its development and signaling regulatory approval for use in Europe.
Currently, May Health is conducting its pivotal REBALANCE trial in the United States under the Investigational Device Exemption (IDE), with the goal of securing FDA approval. This trial is a critical step in evaluating the safety and efficacy of the Anavi System in a broader population of women with PCOS-related infertility. Positive outcomes from the REBALANCE trial could position the Anavi System as a valuable new tool for reproductive medicine professionals, enabling them to expand their clinical options and provide personalized care for patients who face challenges with standard treatments.
For Nexpring Health, the investment in May Health aligns directly with the company’s mission to advance fertility care through innovation. As a global leader in ART solutions, Nexpring Health has long supported embryologists, clinicians, and fertility clinics by providing advanced tools, cutting-edge technologies, and comprehensive support designed to enhance clinical practice and improve patient outcomes. This strategic investment strengthens Nexpring Health’s commitment to expanding access to innovative solutions that empower reproductive medicine professionals while offering hope to patients seeking to start a family.
Wil Boren, President and CEO of Nexpring Health, emphasized the company’s philosophy regarding its role in advancing reproductive care: “At Nexpring Health, we believe our role as a global leader in assisted reproductive technology (ART) solutions extends beyond the products we manufacture. It’s about advancing fertility care in every way possible—for clinicians on the front line, for embryologists working tirelessly in laboratories, and ultimately, for the patients whose hopes and dreams depend on this progress. May Health is doing exactly the kind of work that can change patient outcomes, expand clinical options, and advance this field, and we are proud to support them.”
Boren’s statement highlights the broader vision of Nexpring Health, which goes beyond providing laboratory instruments and ART solutions. The company aims to transform fertility care by investing in technologies that offer novel approaches to challenging clinical conditions such as PCOS-related infertility. By supporting companies like May Health, Nexpring Health reinforces its dedication to improving patient outcomes and expanding the capabilities of fertility care providers worldwide.
From May Health’s perspective, the partnership with Nexpring Health represents a significant step forward in their mission to address the unmet needs of women with PCOS-related infertility. H. Martin Seidel, spokesperson for May Health, commented on the strategic alignment of the two companies’ goals: “For too long, women suffering from PCOS-related infertility have needed more options to help them start a family. Thanks to the continued support of our current investors, we are making significant progress in recruiting for the REBALANCE trial and are preparing to commercialize the Anavi System in Europe and the United States. We are pleased to welcome Nexpring Health to the consortium and look forward to the strong convergence of our two organizations’ missions.”
The collaboration between Nexpring Health and May Health exemplifies a growing trend in the fertility care industry, where technology-driven partnerships are leveraged to address complex reproductive health challenges. By combining Nexpring Health’s global expertise in ART solutions with May Health’s innovative therapeutic approach, this partnership has the potential to reshape how clinicians manage PCOS-related infertility. The integration of novel interventions like the Anavi System into routine clinical practice could reduce the reliance on more invasive procedures, streamline treatment protocols, and ultimately improve success rates for patients seeking to conceive.
In conclusion, the strategic investment by Nexpring Health in May Health underscores a shared commitment to advancing reproductive health through innovation. With PCOS affecting millions of women worldwide, the Anavi System offers a promising solution for patients who have struggled to conceive through conventional treatments. Through continued development, rigorous clinical evaluation, and strong collaborative partnerships, Nexpring Health and May Health are poised to make a meaningful impact on the field of fertility care, providing new hope and expanded options for women and families navigating the challenges of infertility.
This partnership represents not just a financial investment but a shared vision for the future of reproductive medicine—one where technological innovation, clinical expertise, and patient-centered solutions converge to redefine what is possible in fertility care.